Eco AH sees stronger demand from Asia


UK-based Eco Animal Health said its revenue and pre-tax earnings would likely exceed market expectations this year after stronger-than-expected demand for its Aivlosin drug in Asia. “Our business has delivered good progress in key international markets, especially Asia,” CEO David Hallas said. Aivl...

Sign in  as a member, or Join our Community  for free to unlock the full article.